IRCT20260701070040N1 IRCT 2026-08-08 Pak Emirates Military Hospital Rawalpindi Antihypertensive efficacy of valsartan versus telmisartan in young adults with essential hypertension VAlsartan vs Telmisartan Trial (VAST) A randomized controlled trial comparing the antihypertensive efficacy of valsartan versus telmisartan in young adults with essential hypertension 2026-08-15 anticipated 126 Recruiting https://irct.ir/trial/92111 interventional Randomization: Randomized, Blinding: Single blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Other design features: A prospective, single-center, parallel-group randomized controlled trial with 1:1 allocation. Eligible participants with newly diagnosed essential hypertension will be randomized to receive either valsartan 160 mg once daily or telmisartan 80 mg once daily for 12 weeks. Blood pressure will be measured at baseline and during scheduled follow-up visits using a standardized protocol and calibrated equipment. Analysis will be performed according to the intention-to-treat principle, Randomization description: Participants will be randomly allocated (1:1) to valsartan or telmisartan using a computer-generated block randomization sequence. Allocation will be concealed using sequentially numbered, opaque, sealed envelopes opened only after participant enrollment and informed consent, Blinding description: This is a single-blind trial in which participants will be unaware of their treatment allocation. The treating physician responsible for prescribing the medication will know the assigned intervention, while participants will remain blinded throughout the study. Blood pressure measurements and follow-up assessments will be performed according to a standardized protocol. 4 Essential Hypertension. Intervention 1: Intervention group: Participants will receive telmisartan 80 mg orally once daily for 12 weeks along with standard lifestyle modification advice. Blood pressure will be monitored at baseline and follow-up visits. Intervention 2: Control group: Participants will receive valsartan 160 mg orally once daily for 12 weeks along with standard lifestyle modification advice. Blood pressure will be monitored at baseline and follow-up visits. No - There is not a plan to make this available Justification or reason for not sharing IPD is There is no current plan to share individual participant data because of participant confidentiality and institutional data-sharing policies.